Результаты поиска

Antibodies to watch in 2026.

The Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics. Since the first article was published in 2010, the late-stage pipeline has grown from 26 antibody therapeutics to over 200, while during the same time numerous molecules in late-stage studies either transitioned to regulatory review and were approved or were terminated. In this installment of the series, we recap first marketing approvals granted to 19 antibody therapeutics in 2025, discuss 26 molecules currently in r

Combined chemotherapy with sequential allogeneic hematopoietic stem cell transplantation successfully treats primary plasma cell leukemia: a case report.

Primary plasma cell leukemia (pPCL) is an extremely aggressive and rare subtype of plasma cell neoplasm with extremely poor prognosis, and optimal treatment strategies remain controversial due to its low incidence. This case is unique in that it reports long-term disease-free survival after combination chemotherapy followed by allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT), which provides valuable real-world evidence supporting the potential curative role of this sequential therapeutic approach for pPCL, a disease where long-term survival is rarely achieved wi

Совпадение в полном тексте источника
… In July 2017, the initial tracheotomy was performed because of severe dyspnea at a hospital in Beijing. One piece of subglottic mass was surgically resected. The specimen was grayish-red in appearance, with a size of 0.7 × 0.5 × 0.3 cm. Pathological examination confirmed a plasma cell neoplasm. …

Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma.

BackgroundMultiple myeloma (MM) is one of the hitherto incurable malignant blood tumors. Bortezomib plays an important role in the treatment of MM.ObjectiveWe aimed to compare effectiveness, safety, and pharmacoeconomic evaluations of the original research drug and the generic drug Bortezomib in the treatment of MM, so as to provide a reasonable basis for the selection of drugs in clinical diagnosis and treatment.MethodsA collection of 374 patients with MM were diagnosed and treated with combined Bortezomib in our hospital from July 2019 to January 2020.Two hundred and sixty nine cases met the

Совпадение в полном тексте источника
… Ethics Approval The study/data collection was conducted after approval by the Ethics Committee of Beijing Chao-yang Hospital, Capital Medical University (Approval reference number: 2019-4-15–4). 2. Methods 2.1. …

In Vivo Murine Model of Leukemia Cell-Induced Spinal Bone Destruction.

Osteolytic bone lesions can be a consequence of leukemic bone infiltration or focal bone destruction by inflammatory factors released from leukemic cells. Destructive bone lesions have a negative impact on the quality of life of leukemia patients, causing unbearable pain and, in some cases, limb paralysis. However, the mechanism, by which leukemic cells produce destructive bone lesions, and the effect of therapeutics on osteolytic lesions have not been fully elucidated yet and, thus, stand to benefit from an in vivo model. To that end, HL-60 cells were transformed by retrovirus-mediated consti

Совпадение в полном тексте источника
… All experiments involved unconditioned 6- to 8-week-old NOD/SCID mice (Beijing Vital River Laboratory, China) housed under positive pressure in individually ventilated cages. The in vivo model was established after injection of 5 × 10 5 transformed HL60 cells by the tail vein method. …

The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.

Over the past decade, chronic lymphocytic leukaemia (CLL) treatment has shifted from chemoimmunotherapy to targeted oral agents, predominantly Bruton's tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor venetoclax. These therapies have significantly improved outcomes and are now established as first-line treatment options. However, CLL remains incurable, and resistance or intolerance to both drug classes (double-refractory disease) is an emerging challenge. This has driven the development of novel therapeutic strategies, including non-covalent BTKis such as pirtobrutinib and nemtabruti

Совпадение в полном тексте источника
… Orelabrutinib Orelabrutinib (ICP-022, Hibruka, InnoCare, Beijing, China) is a next-generation cBTKi that demonstrated in vitro greater selectivity against BTK than ibrutinib, with a more than 90% BTK inhibition rate [ 31 ]. … Mesutoclax Mesutoclax (ICP-248, InnoCare Pharma, Beijing, China) is a novel, orally bioavailable BCL-2 selective inhibitor. In a phase 1 study, 68 patients were enrolled in the dose escalation and expansion study (# NCT05728658 ) [ 78 ]. …

Construction of CXCR4 Receptor-Targeted CuFeSe2 Nano Theranostic Platform and Its Application in MR/CT Dual Model Imaging and Photothermal Therapy.

INTRODUCTION: Targeting, imaging, and treating tumors represent major clinical challenges. Developing effective theranostic agents to address these issues is an urgent need. METHODS: We introduce an "all-in-one" tumor-targeted theranostic platform using CuFeSe2-based composite nanoparticles (CuFeSe2@PA) for magnetic resonance (MR) and computed tomography (CT) dual model imaging-guided hyperthermia tumor ablation. Plerixafor (AMD3100) is bonded to the surface of CuFeSe2 as a targeting unit. Due to the robust interaction between AMD3100 and the overexpressed Chemokine CXC type receptor 4 (CXCR4

Совпадение в полном тексте источника
… N-hydroxysuccinimide-polyethylene glycol-maleimide imide (NHS-PEG-Mal) was purchased from JenKem (Beijing, China). … Animal procedures involving BALB/c nude mice (Sipeifu, Beijing), weighing 15–22 g, females aged 6–8 weeks, were performed in accordance with institutional animal regulations outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised …

COVID-19 Vaccination in Cancer Patients: A Review Article.

Coronavirus disease 2019 (COVID-19) infection is caused by severe acute respiratory syndrome coronavirus 2. Adults with cancer are immunocompromised due to several causes including cancer itself and immunosuppressive therapy. Thus, cancer patients are more susceptible to develop COVID-19 infection. As COVID-19 vaccines became available, patients with cancer would benefit from receiving the vaccine. This article aims to review the recent evidences and recommendations about COVID-19 vaccination in cancer patients.Current guidelines recommend that patients with cancer should have the priority to

Совпадение в полном тексте источника
… These vaccines are; Pfizer-BioNTech, Oxford/AstraZeneca, Serum Institute of India (Oxford/AstraZeneca formulation), Janssen (Johnson & Johnson), Moderna, Sinopharm (Beijing), Sinovac, Bharat Biotech, Novavax, Serum Institute of India (Novavax formulation). … S® | 12th March 2021 | (Ad26.COV2-S [recombinant]) | Moderna:Spikevax® | 30th April 2021 | mRNA vaccine (nucleoside modified) | Sinopharm (Beijing) Covilo® | 07th May 2021 | Inactivated vaccine (vero cell) | SinovacCoronaVac® | 01st June 2021 | Inactivated vaccine (vero cell) | Bharat BiotechCovaxin …

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.

ImportanceOf approximately 9 million patients with cancer in China in 2020, more than half were diagnosed with late-stage cancers. Recent regulatory reforms in China have focused on improving the availability of new cancer drugs. However, evidence on the clinical benefits of new cancer therapies authorized in China is not available.ObjectiveTo characterize the clinical benefits of cancer drugs approved in China, as defined by the availability and magnitude of statistically significant overall survival (OS) results.Design, setting, and participantsThis mixed-methods study comprising a systemati

Совпадение в полном тексте источника
… Drug labels were obtained from the publicly available data provided by the Center for Drug Evaluation, 23 , 24 manufacturer websites, and the Beijing Cancer Hospital. 25 Regulatory review documents summarize the evidence supporting indication approvals. … Accessed June 30, 2022. https://www.cde.org.cn/hymlj/index 25 Beijing Cancer Hospital . Home page. Accessed July 31, 2021. https://www.bjcancer.org/html/index.html 26 PharmaCube . NextPharma new drug platform. …

Increased risk of cardio-cerebrovascular disease after hematopoietic cell transplantation in patients with previous history.

BackgroundThe impacts of previous cardio-cerebrovascular disease (pre-CCVD) on the outcomes of hematopoietic cell transplantation (HCT) are not well described. Patients with pre-CCVD may often be poor candidates for HCT. This study aimed to investigate the impact of pre-CCVD on transplant outcomes.MethodsA retrospective study was conducted between patients with and without pre-CCVD who consecutively received allogeneic or autologous HCT between November 2013 and January 2020 with a matching of age and disease status. The cardiovascular complications and HCT outcomes of the two groups were eval

Совпадение в полном тексте источника
… Funding This work was partially supported by grants from the Beijing Nova Program (No. 2011114), the National Natural Science Foundation of China (Nos. 82070178 and 81700122), the Beijing Natural Science Foundation of China (Nos. 7172200 and 7132217), the Capital's Funds for Health Improvement and Research …

CeRNA Expression Profiling Identifies KIT-Related circRNA-miRNA-mRNA Networks in Gastrointestinal Stromal Tumour.

Gastrointestinal stromal tumours (GISTs) are the most common human sarcomas and are typically located in the stomach or small intestine. Although circular RNAs (circRNAs) reportedly play vital roles in tumour oncogenesis and progression, the molecular basis of the aggressive tumour biology of these circRNAs in GISTs remains unclear. In this study, we applied SBC ceRNA microarrays to screen for tumour-specific circRNA profiles in GISTs and identified that a total of 5,770 circRNAs and 1,815 mRNAs were differentially expressed in GISTs. Three significantly differential circRNAs (circ_0069765, ci

Совпадение в полном тексте источника
… RNA Purification and SBC ceRNA Microarrays The total RNA was isolated and purified with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and a TIANGEN total RNA Isolation Kit (TIANGEN, Beijing, China) according to the manufacturer’s protocol. The isolated RNAs were stored at −80°C. … Therefore, to distinguish the expression between the linear mRNA and circRNA, total RNAs were incubated for 20 min at 37°C with or without RNase R (Epicentre Technologies, Madison, WI), and the resulting RNAs were purified using an RNAsimple Total RNA Kit (Tiangen, Beijing, China) and transcribed into …

Abstract

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Рекомендации Международной группы по работе с миеломой по диагностике и лечению изолированных плазмоклеточных опухолей.

Одиночные плазмоклеточные опухоли (СП) — редкие локализованные опухоли клоновых плазмоклеток, либо в костной ткани (одиночная костная плазмоклеточная опухоль), либо в мягких тканях/экстраоссозных (экстромедуллярные) с отсутствием или минимальным проникновением в костный мозг (КМ) (<10% клоновых плазмоклеток по иммуногистохимии) и отсутствием признаков системного вовлечения или событий, определяющих миелому. Приблизительно 50% СП прогрессируют в симптоматическую миелому в течение 5 лет после начальной определенной локальной радиотерапии. Увеличение доступности улучшенных диагностических и монит

Совпадение в полном тексте источника
… Wen-Ming Chen, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China 52. Marta Chesi, Mayo Clinic, Scottsdale, AZ 53. J. Anthony Child, University of Leeds, Leeds, United Kingdom 54. Chor Sang (James) Chim, University of Hong Kong, Queen Mary Hospital, Hong Kong, China 55. … Jin Lu, Peking University People's Hospital; Beijing University, Beijing, China 199. Heinz Ludwig, Wilhelminen Cancer Research Institute; Clinic Ottakring, Vienna, Austria 200. Deepu Madduri, Stanford University, Stanford, CA 201. Anuj Mahindra, Scripps Green Hospital, La Jolla, CA 202. …

CAR-T cell therapy for cancer: current challenges and future directions.

Chimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed/refractory (R/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells. However, this approach has yet to be approved for acute myeloid leukemia (AML), the most common acute leukemia in adults and the elderly. Simultaneously, CAR-T cell therapies continue to face significant challenges in the treatment of solid tumors. The primary challenge in developing CAR-T cell therapies for AML is the absence of an ideal target antigen that is both effec

Никотинамид Аденин динуклеотид дополняет Cuprizone испытуемые многочисленные поведенческие изменения в C57BL/6J Mice.

ЦЕЛЬ: Изучение вопроса о том, может ли добавка никотинамида аденина динуклеотида (NAD+) улучшить поведенческие изменения в модели мыши, опьяненной мышью. МЕТОДЫ: Six- Неделю назад мыши C57BL/6J были разделены на three группы: two еда 0.2% cuprizone chow (cuprizone и cuprizone + NAD+ группы), а другая группа получила нормальную грызуновую (контрольную группу) 4 недель. Мыши в чашезоне + NAD+ группа получили 250 мг/кг/сут NAD+ interperitononyly один раз в день, в то время как другие мыши получали засос одновременно. Были проведены поведенческие тесты на пространственное воспоминание (Моррисский

Совпадение в полном тексте источника
… At the start of the experiment, the two treatment groups (CPZ+NAD+ group and CPZ group) were fed 0.2% cuprizone (w/w) (Sigma) rodent chow (Beijing Keao Xieli Feed Co. Ltd.), and the control group (Ctrl group) was fed normal rodent chow. …

Elbow hemiarthroplasty with a 3D-printed prosthesis for distal humeral bone defects after tumor excision: a case report.

INTRODUCTION: The distal humerus is a rare site for primary and metastatic bone tumors. Due to the scarcity of cases and lack of standardized surgical strategies, it is often difficult for surgeons to choose the right choice. The application of a 3D-printed prosthesis with hemiarthroplasty for the treatment of the distal humerus after tumor resection can be a very effective option. CASE PRESENTATION: We present a clinical case of a 3D-printed distal humeral prosthesis for the treatment of bone defects caused by metastatic bone tumors. The preoperative evaluation was aggressively performed, an

Совпадение в полном тексте источника
… We share a patient with a metastatic tumor of the distal humerus with pathological fracture after successfully utilizing DHH treatment, who underwent reconstruction with a construct designed for joint stabilization and augmentation with a 3D-printed distal humeral prosthesis (Chunli, Beijing China). …

Effects of cyclophosphamide combined with prednisone on TNF-α expression in treatment of patients with interstitial lung disease.

Effects of cyclophosphamide combined with prednisone on TNF-α expression in the treatment of patients with interstitial lung disease (ILD), and its clinical significance were investigated. A prospective analysis was performed on 198 patients with ILD in Jinan Central Hospital Affiliated to Shandong University from January 2010 to December 2017. Among them, 101 patients treated with cyclophosphamide combined with prednisone were assigned in the combined treatment group, and 97 patients treated with prednisone alone in the control group. Patients in the two groups were compared in terms of lung

Совпадение в полном тексте источника
… Statistical analysis SPSS 17.4 software (Beijing NDTimes Technology Co., Ltd.) was used for statistical analysis. Enumeration data were expressed as n (%) and tested by Chi-square test. …

Loss of EGFR activity in skeletal stem/progenitor cells is associated with impaired fracture healing in aged mice.

The cellular and molecular events responsible for fracture healing becoming delayed with aging remain unclear. Epidermal growth factor receptor (EGFR) signaling has been reported to play a critical role in bone regeneration. However, knowledge of its specific function in skeletal stem cells during aging-induced fracture delayed union remains scant. In the present study, we first demonstrated that EGFR activity in skeletal stem/progenitor cells decreased as mice aged and thus resulted in delayed fracture healing. To further investigate whether the EGFR signaling can be targeted as a potential t

Совпадение в полном тексте источника
… Bioinspired gradient scaffolds for osteochondral tissue engineering Exploration (Beijing, China) 3 2023 20210043 10.1002/exp.20210043 PMC10624381 37933242 22 Shi R. Zhan H. Jiang S. … Piezoelectric stimulation enhances bone regeneration in alveolar bone defects through metabolic reprogramming of macrophages Exploration (Beijing, China) 4 2024 20230149 10.1002/exp.20230149 PMC11657998 39713207 26 Li P. Deng Q. Liu J. …

ATF3/SLC31A1-Mediated Cuproptosis Contributes to Bortezomib-Induced Peripheral Neurotoxicity and Intervention by (-)-Epigallocatechin Gallate.

Bortezomib (BTZ), the first-generation proteasome inhibitor, has been approved for the treatment of relapsed, refractory, and newly diagnosed multiple myeloma. Despite its remarkable antitumor efficacy, BTZ treatment is severely limited by a high incidence of systemic adverse reactions, primarily due to its non-selective cytotoxicity toward rapidly dividing normal cells and its potent neurotoxic effects on peripheral neurons. Bortezomib-induced peripheral neurotoxicity (BIPN) manifests as neuropathic pain and sensory abnormalities, affecting up to 31% to 64% of patients and limiting BTZ's clin

Совпадение в полном тексте источника
… Animal Study and Treatment Adult male C57BL/6J mice weighing approximately 25 g were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). …

Исследования &quot; горячих точек &quot; и тенденций в области электрической стимуляции нарушений движения: библиометрический анализ на основе 2016 в адрес 2025.

Лечение электрической стимуляции стало важнейшим средством борьбы с нарушениями, связанными с движением. Однако быстро расширяющийся и фрагментированный объем литературы требует макроскопической оценки для выявления глобальных сетей сотрудничества и формирующихся научных границ. В связи с этим в рамках этого исследования был проведен всеобъемлющий визуализационный анализ исследовательских тенденций и &quot; горячих точек &quot; в этой области для определения эволюционной траектории и определения будущих терапевтических изменений. Публикации 2016 в адрес 2025 были найдены в Web of Science Core

Совпадение в полном тексте источника
… This work was supported by Sanming Project of Medicine in Shenzhen (No.SZSM202211025), the Guangdong Basic and Applied Basic Research Foundation 2025A1515010859, the Fund for Undergraduate Research Projects of Beijing University of Chinese Medicine (grant numbers BKKY26002 and BKKY26011) grants from … the Beijing University of Chinese Medicine College Student Innovation and Entrepreneurship Training Program Project (X202510026046, X202510026003, X202510026048, X202510026102, and X202310026158). …

Cellular immunotherapy for hematological malignancy: recent progress and future perspectives.

Advancements in the field of cellular immunotherapy have accelerated in recent years and have changed the treatment landscape for a variety of hematologic malignancies. Cellular immunotherapy strategies exploit the patient's immune system to kill cancer cells. The successful use of CD19 chimeric antigen receptor (CAR) T-cells in treating B-cell malignancies is the paradigm of this revolution, and numerous ongoing studies are investigating and extending this approach to other malignancies. However, resistance to CAR-T-cell therapy and non-durable efficacy have prevented CAR-T-cells from becomin

Совпадение в полном тексте источника
… Consequently, Professor Bacigalupo from Italy has commented that the “Beijing Protocol from China and PT-Cy Protocol from the US are currently the 2 major haploidentical platforms worldwide,” in 2020 EMBT E-Learning. … vs. 43% ( P = 0.023 ), relapse 23% vs. 47% ( P = 0.006 ) Yu, 2019 | High-risk AML | 83 vs. 106 | G-CSF and ATG | 3-year RFS 63% vs. 43% ( P = 0.035 ), relapse 14% vs. 24% ( P = 0.101) Huang’s group has led several disease-specific, multi-center studies comparing outcomes between HIDs by using the Beijing …